US seniors cut back on drugs, AARP warns

25 May 2008

The AARP, which represents US senior citizens and is one of the largest advocacy groups in the country, has published details of a nationwide survey to determine how people aged 45 and older are responding to the current economic slowdown. The main finding is that a majority of those 45 or older believe the economy is in bad shape and that many have adapted their spending behavior. Two thirds of respondents (66%) reported having difficulty paying for food, gas, utilities and prescription drugs. Cutting back on medicines was cited more often as an option chosen by 45-55 year-olds than by the over 65s, partly reflecting the safety net provided by the Medicare Part D prescription drug program (Marketletters passim). However, the AARP arguesthe older generation had already cut its spending providing less margin to do so at present.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight